Investment Case
Why invest in Cline?
Developing the next generation of products and treatments for patients
Cline Scientific is a life science company with a vision to offer unique and life-changing medical solutions in cancer diagnosis and regenerative medicine to improve life for patients. The company achieves this by using its patented nanotechnology.
Unique nanotechnology that offers solutions to unresolved challenges
This nanotechnology is a method for producing gradient surfaces on a nanoscale and consists of a surface coated with several million nanoparticles. This nanotechnology can be used in several research areas and offers new solutions to unresolved challenges. Cline has two ongoing projects, one project in metastatic cancer diagnostics (CellRACE) and one project in stem cell-based therapy for osteoarthritis (StemCART).
Significant market potential within cancer diagnostics and stem cell therapy
Cline’s current projects have substantial market potential, with both segments having pools of patients in need in the tens of millions. In both areas, there is a strong need for improved and more precise diagnostics methods and tailored therapy products to treat the underlying diseases.
Cutting edge stem cell-derived cartilage repair therapy – StemCART
StemCART is Cline’s stem cell therapy project where the company is developing a solution to fight osteoarthritis. Today, it is estimated that 16% of the world's population suffers from osteoarthritis [1]. StemCART will offer an allogeneic stem cell therapy to fight osteoarthritis by implanting uniquely produced cells that can heal cartilage, which is currently not possible. This is achieved by using the company's gradient surfaces to cultivate a precise and homogeneous cell population which under optimal conditions develops into chondrocytes, the cells present in cartilage tissue. After a condensation phase, the cells reach the stage required for the healing of an injury. These newly created cartilage cells are integrated into a matrix that can be implanted in the patient's joints to replace degraded cartilage.
Breakthrough cancer diagnostic product for detecting risk for metastasis – CellRACE
CellRACE is Cline’s cancer diagnostics project where the company is developing a diagnostic product to assess the risk of spreading a tumor (metastasis). Today, 90% of all cancer-related deaths are due to metastases [2]. CellRACE will be able to assess the probability of whether the cells in the tumor will form metastases or not. This is done with the help of the company's gradient surfaces that can simulate the cell environment among living tumor cells. Hence, clinicians will be able to understand how the living tumor cells behave over time. Unlike CellRACE, today’s methods such as histology and biomarkers cannot assess the tumor’s current behavior and are based on historical data. CellRACE addresses an unmet problem and facilitates the application of the right type of treatment, thus reducing the risk of overtreatment with aggressive chemotherapy. The company is currently conducting development focusing on breast cancer, but the technology is meant to be adapted to other types of metastasizing cancers as well.
An attractive business model with several potential revenue streams
With its technology, know-how, and research, Cline will drive these projects into clinical trials. The goal is to find a commercial partner in the form of Big Pharma who will take the various projects to market, either through licensing or acquisition of the project. Cline also has the opportunity to license out application areas outside the company's focus areas.
[1] Cui, A., Li, H., Wang, D., Zhong, J., Chen, Y., & Lu, H. (2020). Global, regional prevalence, incidence and risk factors of knee osteoarthritis in population-based studies. EClinicalMedicine. 2020; 29: 100587.
[2] Chaffer, C. L., & Weinberg, R. A. (2011). A perspective on cancer cell metastasis. Science, 331(6024), 1559-1564.
Become a shareholder here:
Investments in financial instruments are associated with financial risk. Investments can increase or decrease in value or become completely worthless. An investment that historically has had a good value development is no guarantee for the future.
Links
Teaser (Analyst Group) –
https://www.analystgroup.se/wp-content/uploads/2022/03/Analyst-Group-Cline-Scientific-Analys-TEASER.pdf
Analysis (Analyst Group) –
https://www.analystgroup.se/wp-content/uploads/2022/03/Analyst-Group-Cline-Scientific-Analys-Q4-21.pdf